AI-generated analysis. Always verify with the original filing.
DiaMedica Therapeutics reported full-year 2025 financial results with increased net loss to $32.8 million, R&D expenses up to $24.6 million, and cash position of $59.9 million supporting operations through 2H 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
of this report. The information contained in Item 2.02 of this report and Exhibit 99.1 to this report shall not be deemed to be “filed” with the United States S
| Financial Statements and Exhibits. | |---|---| | | (d) | Exhibits . | |---|---|---| | | Exhibit No. | | Description | |---|---|---|---| | | 99.1 | | Press Rel
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $24.6K | GAAP |
| General and Administrative Expenses | $9.8K | GAAP |
| Total Operating Expenses | $34.4K | GAAP |
| Operating Loss | $-34.4K | GAAP |
| Net Loss | $-32.8K | GAAP |
| Basic and Diluted Net Loss per Share | $-0.70 | GAAP |